FDA schedules first oncology advisory panel in nine months, will review AstraZeneca candidates

The FDA announced it will hold an oncology advisory committee meeting roughly nine months from now.

The meeting will focus on evaluating a pair of investigational drugs from AstraZeneca, though details of the compounds were not disclosed.

This will be the agency’s first oncology advisory panel in nearly a year, indicating renewed regulatory attention on cancer therapeutics.

The outcome could influence the timing of any future submissions or approvals for the AstraZeneca products.